Infection with group A streptococcus (GAS) can lead to a plethora of illnesses and diseases, including pharyngitis, pyoderma, invasive diseases, rheumatic fever (RF), and rheumatic heart disease (RHD). It has been estimated that, collectively, GAS infections can cause 1500,000 deaths each year, the majority of which are related to RF and RHD [1] . The burden of GAS diseases is greater in less-developed countries and in indigenous populations of developed countries. Of note, the in-digenous population of Australia has been reported to have the highest incidence of RF in the world [2] .
To prevent GAS infection, research has focused on the development of a vaccine based on the M protein, the antiphagocytic bacterial surface protein that is the primary virulence factor [3] . Previous studies have indicated that protective immunity to GAS can be evoked by opsonic antibodies against serotypic epitopes at the amino-terminal region of the M protein that are type specific [4, 5] . The M protein, however, is highly variable, with 1150 different types having been identified to date. With the aim of developing a vaccine that has broad strain coverage, several strategies have been used to overcome the variability of the M protein, including designing recombinant multivalent vaccines that contain multiple serotypic epitopes [6, 7] , vaccines that are based on the conserved carboxy-terminal C-repeat region [8] [9] [10] [11] [12] [13] [14] [15] , and vaccines that incorporate serotypic and conserved-region determinants [16] [17] [18] ; the last may be more advantageous in providing better protective immunity. Chemical structure of the lipid core peptide (LCP) vaccine constructs. The LCP constructs were synthesized to contain three 2-aminododecanoic acid residues, 2 glycine (Gly) spacers, and 2 copies each of 4 (A), 3 (B) , or 2 (C) group A streptococcus peptide epitopes. The peptide epitopes are attached to the amino groups of the lysine (Lys) residues of a polylysine core. The tetraepitopic LCP vaccine construct, LCP-J8-8830-NS1-PL1, contains J8 (QAEDKVKQSREAKKQVEKALKQLEDKVQ) at position (P) 1, 8830 (DNGKAIYERARERALQELGP) at P2, NS1 (RVTTRSQAQDAAGLKEKAD) at P3, and PL1 (EVLTRRQSQDPKYVTQRIS) at P4 (A). The triepitopic LCP construct, LCP-J8-8830-NS1, contains J8 at P1, 8830 at P2, and NS1 at P3 (B). The diepitopic LCP constructs, LCP-J8-8830 and LCP-NS1-PL1, contain J8 at P1 and 8830 at P2 or NS1 at P1 and PL1 at P2.
We have previously investigated the lipid core peptide (LCP) vaccine delivery system [19] for the delivery of a GAS lipopeptide vaccine based on the conserved C-repeat region of the M protein [10] . Although epitopes of M proteins exist within the carboxyterminus-including the C-repeat region [20] [21] [22] -that can induce antibodies and T cells that are cross-reactive with human tissues, a conformationally constrained, minimally conserved peptide, J8, that lacks a T cell autoepitope [22] from the M protein has been identified [23, 24] . Our experiments demonstrated that an LCP vaccine formulation [10] containing multiple copies of the J8 epitope elicited opsonic antibodies in mice. Furthermore, parenteral delivery of an LCP vaccine formulation containing J8 and a serotypic epitope evoked complete protection after homologous GAS challenge [17] .
The present study investigated the LCP system for the incorporation of 4 different nonhost cross-reactive peptide epitopes of the GAS M protein into a single immunogen. Mice were immunized with a tetraepitopic LCP vaccine construct, and the immunogenicity of the vaccine candidate was evaluated by measuring antigen-specific antibody responses in serum. In addition, we evaluated the induction of serum opsonic antibodies, bacterial surface binding, and protection against GAS infection after challenge.
MATERIALS AND METHODS
Design of a tetraepitopic LCP vaccine construct. We designed a GAS vaccine candidate, LCP-J8-8830-NS1-PL1, containing 3 amino-terminal serotypic epitopes-8830 (DNGKAIYERAR-ERALQELGP), NS1 (RVTTRSQAQDAAGLKEKAD), and PL1 (EVLTRRQSQDPKYVTQRIS)-from GAS isolates that are common in Australian Aboriginal communities in the Northern Territory [16] , a region highly endemic for GAS. To generate a vaccine construct with broader strain coverage, we also included a conformational epitope, J8 (QAEDKVKQSREAKKQVEKA-LKQLEDKVQ), from the conserved carboxy-terminal C-repeat region [23, 24] . One triepitopic LCP construct, LCP-J8-8830-NS1, and 2 diepitopic LCP constructs containing either the J8 and 8830 or the NS1 and PL1 GAS peptide epitopes-LCP-J8-8830 and LCP-NS1-PL1, respectively-were also designed, for use in comparative experiments with the tetraepitopic LCP construct. Synthesis of LCP constructs. The diepitopic LCP constructs, LCP-J8-8830 and LCP-NS1-PL1, which contained three 2-aminododecanoic lipoamino acid (LAA) residues and 2 copies of either the J8 and 8830 or the NS1 and PL1 peptide epitopes, were synthesized on 4-methylbenzhydrylamine (MBHA) resin by use of tert-butoxycarbonyl (Boc) chemistry, as described elsewhere [17] . The triepitopic construct, LCP-J8-8830-NS1, also contained 2 copies of the NS1 peptide epitope, in addition to J8 and 8830. The tetraepitopic LCP construct, LCP-J8-8830-NS1-PL1, included 2 copies of all 4 GAS peptide epitopes. In all constructs, a glycine spacer was used between the MBHA resin and the first C12-LAA residue as well as between the second and third C12-LAA residues. To introduce different peptide epitopes into the LCP system, orthogonally protected Boc-Lys(FMOC)-OH was used. Each LCP construct was removed from the resin by use of hydrogen fluoride and was characterized by SDS-PAGE and electrospray ionization mass spectrometry. The molecular weights of the LCP constructs were 20,415 Da for LCP-J8-8830-NS1-PL1, 16,818 Da for LCP-J8-8830-NS1, 12,344 Da for LCP-J8-8830, and 9905 Da for LCP-NS1-PL1. The chemical structure of the LCP constructs is shown in figure 1 .
Mice and immunization. All protocols were approved by the Bancroft Centre Research Animal Ethics Committee, in compliance with Australian National Health and Medical Research Guidelines. On day 0, B10.BR (H-2 k ) mice ( per n p 10 group; Animal Resource Centre) either were inoculated subcutaneously (sc) at the tail base with 30-60 mg of LCP construct emulsified 1:1 with complete Freund's adjuvant (CFA) or were given LCP construct at the same dose level without CFA in a total volume of 50 mL of sterile-filtered PBS. Control mice received either 30 mg of 8830 peptide in CFA, 30 mg of J8 peptide plus 8830 peptide in CFA, 30 mg of diphtheria toxoid (dT)-conjugated NS1 peptide plus PL1 peptide (NS1-dT plus PL1-dT) [12] in CFA, CFA alone, or PBS alone. Three weeks after the primary immunization, mice received 4 booster immunizations of immunogen (3 mg each) given at weekly intervals in PBS (days 21, 28, 35, and 42), before the collection of blood on day 50. Mice received an additional booster immunization on day 163, before the collection of more blood on days 170 and 290.
Detection of murine antibodies. ELISA was used for the measurement of antigen-specific IgG titers in serum, as described elsewhere [17] . Plates were coated with peptides contained in the vaccine candidate, and serum samples were assayed using 2-fold dilutions of a 1:100 dilution of serum. Antibody titers were defined as the highest dilution that gave an optical-density reading at 450 nm of 13 SDs above the mean optical density of control wells containing normal mouse serum.
Bactericidal assay. The ability of murine serum samples to opsonize GAS in vitro was determined by a bactericidal assay, as described elsewhere [17] . Briefly, GAS were incubated at 37ЊC for 3 h in the presence of nonopsonic blood from human donors and heat-inactivated (60ЊC for 10 min) mouse immune serum or control normal mouse serum. GAS were then plated in duplicate on 2% (vol/vol) horse blood agar plates, and col- Immunofluorescence assay. The ability of murine serum antibodies to bind to the bacterial surface was detected by immunofluorescence, using a fluorescein isothiocyanate (FITC)-conjugated secondary antibody. GAS were grown overnight in Todd-Hewitt broth/1% neopeptone and centrifuged at 1600 g for 5 min; the pellet was then resuspended in PBS to an OD 600 nm of 0.1. The bacterial dilution (5 mL) was applied to polylysine microscope slides (Esco), air-dried at room temperature, and fixed for 10 min with 3% paraformaldehyde (Sigma). Slides were washed in PBS (10 min) and blocked with 5% skim milk/0.5% Tween 20 in PBS for 30 min at 37ЊC in a humidified chamber. Slides were rinsed in PBS and incubated with nonspecific human IgG (Serotech) diluted 1:200 with 0.5% skim milk/0.05% Tween 20 in PBS, for 1 h at 37ЊC in a humidified chamber. Slides were then incubated overnight with primary antibody samples diluted 1:200 with 0.5% skim milk/ 0.05% Tween 20 in PBS, at 4ЊC in a humidified chamber. Slides were washed with 2 changes of PBS for 15 min and incubated with FITC-conjugated F(ab ) 2 goat anti-mouse IgG (Silenus) diluted 1:100 with 0.5% skim milk/0.05% Tween 20 in PBS, for 2 h in the dark at room temperature in a humidified chamber. Slides were then washed 3 times in PBS for 30 min and mounted with Vectashield (antifade; Vector Laboratories). Slides were examined using an Axioskop fluorescent microscope, at a detection wavelength of 520 nm.
GAS challenge. Mice were challenged intraperitoneally (ip) on day 60 or 300 after primary immunization with -5 2.0 ϫ 10 cfu of the virulent GAS strain 8830 [17] . In accor- Statistical analysis. The Wilcoxon rank sum test was used for the comparison of antibody titers, and Fisher's exact test was used to compare the proportions of surviving mice between the groups. Significance levels were adjusted for multiple comparisons by use of the Bonferroni correction.
was con-P ! .05 sidered to be statistically significant.
RESULTS AND DISCUSSION
We previously investigated the potential of incorporating a conserved-region peptide epitope and 7 serotypic GAS M protein peptide epitopes into a synthetic multiepitope heteropolymer construct [16] . The M types that were targeted represented ∼13% of GAS isolates that cause hospital and community infections in the Northern Territory of Australia, a region highly endemic for GAS. Immunization of mice with the heteropolymer construct demonstrated excellent immunogenicity and protection against homologous and heterologous GAS strains, indicating its potential as a GAS vaccine candidate [16] . However, in its current form, further development of this technology is limited in that incorporation of peptides onto the polymer's alkane backbone, from which all peptides are pendant, is a random process, resulting in a compound that can exhibit immunological variation between syntheses (authors' unpublished data). It was, therefore, necessary to explore alternative approaches to vaccine design and delivery, to generate a more precise formulation that could potentially satisfy regulatory requirements for possible human application.
In the present study, we investigated the efficacy of the parenteral delivery of an LCP-based GAS vaccine candidate containing 4 different M protein epitopes (J8, 8830, NS1, and PL1) in inducing antigen-specific serum IgG responses. The 3 se- rotypic epitopes originally had been combined in the heteropolymer construct, along with a second, very closely related conserved-region determinant, J14, which was used as an alternative to J8 [16] . All epitopes lacked cross-reactivity to tissue proteins that represented possible target antigens involved in the pathogenesis of RHD [16] . In the tetraepitopic LCP vaccine construct created here, the 4 epitopes were synthesized onto a polylysine core in a well-defined order, in that J8 was synthesized on the first lysine residues, 8830 and NS1 were synthesized on the following lysine residues, and PL1 was synthesized on the last lysine residues farthest from the LAA tail. After sc inoculation of mice with LCP-J8-8830-NS1-PL1 administered with or without CFA, serum titers of IgG against the individual GAS peptide epitopes were determined ( figure 2 and table 1 ). 8830 peptide administered with CFA was included as a positive control (mean antibody titer, ). On day 50 after pri- topic LCP construct in CFA, with mean antibody titers ranging from to . IgG responses in serum decreased 5 6 2.98 ϫ 10 2.46 ϫ 10 over time, although the antibody titers remained high for all epitopes on day 290 after primary immunization. The mean antigen-specific antibody titers detected in mice immunized without CFA on day 50 after primary immunization ranged from to , with titers of antibody against 3 5 4.82 ϫ 10 7.40 ϫ 10 J8 being the lowest. Also, 4 of 9 mice did not elicit a response to J8. A decrease in the antibody responses was observed over time for all 4 GAS peptide epitopes.
It was also important to determine whether increasing the number of epitopes on the LCP had any detrimental effects with respect to the immunogenicity of the individual peptide epitopes represented in the tetraepitopic LCP construct. To address the issue of whether an LCP with fewer peptides would give a better response, the immunogenicity of the tetraepitopic LCP construct was compared with that of the individual diepitopic LCP-J8-8830 and triepitopic LCP-J8-8830-NS1 constructs, because these LCPs were used as the building blocks for the synthesis of the tetraepitopic LCP construct. The data ( figure 3 and table 2) showed that strong 8830-specific responses developed in the mice immunized with these 3 constructs (mean titers up to ), with a decrease in an- 6 1.88 ϫ 10 tibody titers observed as the number of peptides increased. In the mice immunized with the triepitopic LCP construct, no response was elicited to NS1, whereas all of the mice immunized with the tetraepitopic LCP construct developed a response to NS1 ( ). Conversely, J8-specific responses were reduced P ! .05 in the mice immunized with the tetraepitopic LCP. The J8 epitope has previously been demonstrated to be immunogenic when incorporated into an LCP system, either alone or in combination with additional epitopes [10, 17, 18] . The data presented here indicate that increasing the number of epitopes attached to the LCP may limit the effectiveness of some epitopes, particularly those closest to the LCP anchor-in this case, J8. Further studies are necessary to determine, by use of spacer molecules, the positional and spatial arrangements of the different epitopes required to obtain the optimal immunogenicity of a vaccine construct.
As a possible alternative to increasing the number of peptides attached to the same LCP, we also assessed the feasibility of physically mixing 2 different diepitopic LCP constructs and analyzed whether it would be as effective in inducing immune responses as the single 4 peptide-containing immunogen. The data ( figure 3 and table 2) showed that serum antigen-specific IgG responses were similar in the mice immunized with the Figure 6 . Survival of mice challenged intraperitoneally with the 8830 group A streptococcus (GAS) strain after subcutaneous immunization with the tetra-, tri-, or diepitopic lipid core peptide (LCP) vaccine constructs or with a 1:1 mixture of the diepitopic vaccine constructs (LCP-J8-8830 + LCP-NS1-PL1). Mice were challenged with -cfu of the 8830 GAS strain on day 60 (d60) or day 300 (d300) after primary immunization, 5 5 2.0 ϫ 10 4.0 ϫ 10 and death was recorded daily. * , compared with the control mice that received PBS. CFA, complete Freund's adjuvant; tetra-LCP, LCP-J8-8830-P ! .05 NS1-PL1. mixture of diepitopic LCP constructs, compared with those in the mice immunized with the individual diepitopic LCP constructs. The highest IgG response observed was to 8830, followed by J8, NS1, and PL1. These data indicate that antibody response levels were not adversely affected by mixing different LCP constructs. This finding is particularly relevant for the development of multivalent vaccines and raises the possibility of mixing, for example, 2 tetraepitopic LCP constructs that together cover all 8 of the GAS M protein epitopes that were originally included in our heterpolymer construct [16] .
We then compared antibody responses to all 4 GAS peptide epitopes between the mice immunized with the tetraepitopic LCP construct and the mice immunized with the mixture of LCP-J8-8830 and LCP-NS1-PL1. J8-specific IgG titers were decreased in response to the tetraepitopic LCP construct, as was also demonstrated when responses were compared with those in the mice immunized with LCP-J8-8830. In contrast, poor PL1-specific IgG responses were detected in the mice immunized with either the mixture of diepitopic LCP constructs or LCP-NS1-PL1, yet responses were significantly increased (P ! ) after immunization with the tetraepitopic LCP construct. .05 The NS1 and PL1 epitopes are known to be weakly immunogenic in B10.BR (H-2 k ) mice when administered as adjuvanted peptides as opposed to carrier-conjugated peptides (authors' unpublished data). The strong PL1-specific antibody response observed in the mice immunized with the tetraepitopic LCP vaccine construct lends support to use of the LCP delivery system functioning as a carrier, which is necessary for efficient antibody production.
In addition to assessing the immunogenicity of the tetraepitopic LCP construct, we were primarily interested in its potential to induce protective immunity against GAS. One measure by which to assess this is the in vitro GAS opsonization assay. We therefore determined the opsonic activity of serum antibodies against different GAS strains (figure 4), including 3 type-specific homologous strains (8830 GAS, NS1 GAS, and PL1 GAS) that have their amino-terminal serotypic epitopes represented in the construct and 2 nonserotypic heterologous strains (NS27 GAS and M1 GAS) that are known to express the J8 epitope. There was a high degree of opsonization of all GAS strains by immune serum from mice immunized with (range, 44%-79%) or without (range, 48%-60%) additional adjuvant, indicating the induction of broadly protective responses. Immune serum from mice immunized with J8 plus 8830 in CFA was able to opsonize the heterologous M1 and NS27 GAS strains (range, 25%-32%), a finding that is consistent with the generally lower opsonic activity of antibodies elicited against C-repeat-region epitopes of the M protein, compared with that of antibodies elicited against amino-terminal epitopes [17] . A low level of opsonization of 8830 GAS and NS27 GAS by immune serum from mice immunized with NS1-dT plus PL1-dT in CFA was also observed (data not shown) and may be attributable to antibodies elicited against the toxoid [11] . The immunofluorescence assay, used to detect the binding of antibodies to the surface of GAS (figure 5), demonstrated that immune serum from mice immunized with LCP-J8-8830-NS1-PL1 contained antibodies that bound to GAS (∼50%-60% surface binding to 8830 and PL1 GAS; ∼60%-80% to NS1 GAS) with a high degree of intensity, whereas a lower rate of binding to the heterologous M1 GAS strain was observed. There was minimal surface binding (∼5%-10%) of antibodies in immune serum from mice immunized with PBS. Antibodies in immune serum from control mice immunized with NS1-dT plus PL1-dT in CFA showed strong binding to the relevant serotypic NS1 and PL1 GAS strains, and those in immune serum from mice immunized with J8 plus 8830 in CFA showed binding to the serotypic 8830 GAS strain and nonserotypic M1 GAS strain. To evaluate in vivo protection after immunization with the tetraepitopic LCP construct, mice were challenged ip with the homologous 8830 GAS strain on day 60 or 300 after primary immunization. The survival rate in each group was determined for 15 days after challenge (figure 6). Control mice administered 8830 GAS peptide in CFA were completely protected. Among the mice challenged on day 60 after primary immunization, there was significantly increased survival in those immunized with the tetraepitopic LCP construct in the presence or absence of CFA (78% and 90%, respectively), compared with that in the mice in the PBS control group (19% [5/26] 
) (
). P ! .05 Among the mice challenged on day 300 after primary immunization, survival was significantly increased in the mice immunized with the tetraepitopic LCP vaccine construct in the presence of CFA ( ), whereas, in the absence of additional P ! .05 adjuvant, survival was 22%. Immunization with LCP-J8-8830-NS1 (90% survival), LCP-J8-8830 (100% survival), and the mixture of LCP-J8-8830 and LCP-NS1-PL1 (90% survival), but not LCP-NS1-PL1, also showed protection against 8830 GAS challenge. The mean 8830-specific antibody titers for the various groups of immunized mice were plotted against the survival rates for each group after challenge with 8830 GAS ( figure  7) . Linear regression analysis of the data indicated an overall positive correlation between the mean 8830-specific serum IgG titers and the survival rates ( ; ). From this, 2 R p 0.7733 P ! .0004 it can be deduced that, in our murine GAS challenge model, sufficient antibody responses are required to achieve protection against systemic infection, as has previously been demonstrated using a vaccine candidate based solely on the J8 conservedregion determinant [11] .
We have presented data on the immunogenicity and protective potential of a well-defined synthetic multiepitopic GAS vaccine candidate based on the LCP delivery system. We targeted specific M protein serotypic epitopes from GAS isolates common to a region in which GAS is endemic. To expand the coverage potentially afforded by such a vaccine and deliver increased protection, we included a conserved-region determinant that is identical in at least 70% of GAS isolates [25] . We have shown that the vaccine candidate not only induced prolonged antibody responses that were specific to all analyzed epitopes and that could opsonize multiple GAS strains but also induced protective immunity against in vivo GAS challenge. Our preclinical data support the efficacy of the LCP delivery system in the development of a broadly protective vaccine for the prevention of endemic GAS infection.
